

Luisa Foltran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3502987/publications.pdf>

Version: 2024-02-01

26
papers

512
citations

687220

13
h-index

677027

22
g-index

27
all docs

27
docs citations

27
times ranked

1115
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 626275.	1.3	4
2	A LCâ€MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 187, 113358.	1.4	16
3	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	1.9	21
4	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11527.	1.6	13
5	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	1.7	7
6	FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy. <i>Genes</i> , 2019, 10, 276.	1.0	9
7	The Genotype for <i>DPYD</i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	2.3	39
8	Neoadjuvant epirubicin, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4066-4066.	0.8	2
9	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3870-3896.	1.4	70
10	Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 1269-1277.	2.9	55
11	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	0.9	31
12	Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4124-4124.	0.8	5
13	Erlotinib-Associated Interstitial Lung Disease in Advanced Pancreatic Carcinoma: A Case Report and Literature Review. <i>Tumori</i> , 2015, 101, e122-e127.	0.6	4
14	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , 2015, 4, 6828.	1.6	31
15	Prognostic role of <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> mutations in advanced colorectal cancer. <i>Future Oncology</i> , 2015, 11, 629-640.	1.1	49
16	Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience. <i>Oncotarget</i> , 2015, 6, 8255-8260.	0.8	14
17	Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11576-e11576.	0.8	0
18	Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. <i>Supportive Care in Cancer</i> , 2014, 22, 2527-2533.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 648-648.	0.8	1
20	Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts): A retrospective study.. Journal of Clinical Oncology, 2014, 32, 511-511.	0.8	1
21	Offlabel nab-paclitaxel: Gemcitabine chemotherapy in advanced pancreatic cancer – A monoinstitutional experience.. Journal of Clinical Oncology, 2014, 32, e15239-e15239.	0.8	0
22	Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumor Biology, 2013, 34, 131-137.	0.8	49
23	Unplanned presentations of cancer outpatients: a retrospective cohort study. Supportive Care in Cancer, 2013, 21, 397-404.	1.0	48
24	Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast, 2013, 22, 1101-1107.	0.9	16
25	Oxaliplatin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1344-1353.	0.9	10
26	Does multiple mutational analysis of the EGFR pathway have a prognostic role in advanced colorectal cancer (CRC)?. Journal of Clinical Oncology, 2012, 30, 3612-3612.	0.8	0